

2. Sylvia MT, Kumar S. and Dasari P. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables. *Indian J Pathol Microbiol.* 2012; 55:33-7
3. Hahn WC, Weinberg RA. Modeling the molecular circuitry of cancer. *Nat Rev Cancer.* 2002; 2:331-41.
4. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. *Cancer Cell.* 2002; 2: 103-12.
5. Bali A, O'Brien PM, Edwards LS, et al. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. *Clin Cancer Res.* 2004; 10:5168-77.
6. Tachibana M, Watanabe J, Matsushima Y, et al. Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma, and related proteins. *Int J Gynecol Cancer.* 2003; 13:598-606.
7. Corney DC, Flesken-Nikitin A, Choi J, et al. Role of p53 and Rb in Ovarian Cancer. *Adv Exp Med Biol.* 2008; 622:99-117.
8. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. *Proc Natl Acad Sci USA.* 1993; 90:4961-5.
9. Kupryjanczyk J, Bell DA, Dimeo D, et al. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. *Hum Pathol.* 1995; 26:387-92.
10. Skomedal H, Kristensen GB, Abeler VM, et al. P53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumors and stage I carcinomas. *J Pathol.* 1997; 181: 158-65.
11. Zheng J, Benedict WF, Xu HJ, et al. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. *J Natl Cancer Inst.* 1995; 87:1146-53.
12. de Graeff P, Hall J, Crijns APG. Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. *Br J Cancer.* 2006; 95: 627-33.
13. Ramos-Vara JA. Technical Aspects of Immunohistochemistry. *Vet Pathol.* 2005; 42:405-26.
14. The Lancet Oncology: Ovarian cancer: breaking the silence. *Lancet Oncol.* 2012; 13(2):111. doi: 10.1016/S1470-2045(12)70052-9.
15. Levesque MA, Katsaros D, Yu H, et al. Mutant p53 protein expression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. *Cancer.* 1995; 75:1327-38.
16. Berchuck A, Kohler MF, Hopkins MP, et al. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. *Gynecol Oncol.* 1994; 52:232-6.
17. Gannon JV, Greaves R, Iggo R, et al. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. *Embo J.* 1990; 9:1595-602.
18. Van der Zee AG, Hollema H, Suurmeijer AJ, et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. *J Clin Oncol.* 1995; 13:70-8.
19. Thigpen T, Brady MF, Omura GA. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. *Cancer.* 1993; 71(2):606-14.
20. Kerbel HA, Abdul Saheb RH, Alabbasi DS. Expression of p53 and her2/neu in serous ovarian carcinoma with different grades of differentiation (Immunohistochemical Study). *Kufa Med J.* 2011; 14(1):98-107.
21. Hamdi EA, Saleem SH. P53 expression in ovarian tumors: (an immunohistochemical study). *Ann Coll Med Mosul.* 2012; 38(2):73-9.

Correspondence to Dr Haider S. Kadhim

Email: haider_kadhim@yahoo.com

P. O. Box 70056, Al-Kadhimiya, Baghdad, Iraq.

Received 27th Jun. 2012: Accepted 30th Sep. 2013.